Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 7,700 shares, an increase of 28.3% from the February 28th total of 6,000 shares. Based on an average daily volume of 12,600 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.1% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Armata Pharmaceuticals in a research note on Thursday, December 19th.

Armata Pharmaceuticals Price Performance

Shares of ARMP opened at $1.46 on Tuesday. Armata Pharmaceuticals has a 1-year low of $1.34 and a 1-year high of $4.25. The company has a market cap of $52.82 million, a PE ratio of -0.89 and a beta of 0.87.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.